2020
DOI: 10.1097/hs9.0000000000000478
|View full text |Cite
|
Sign up to set email alerts
|

Discordant Response of Systemic Mastocytosis Associated With Myelodysplastic Syndrome After Midostaurin and Allogeneic Hematopoietic Stem‐cell Transplantation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(3 citation statements)
references
References 18 publications
1
2
0
Order By: Relevance
“…Indeed, despite relatively short follow‐up in the EXPLORER and PATHFINDER studies, a non‐insignificant number of patients discontinued treatment due to disease progression 35,36 . Similar findings have been seen in the midostaurin studies 44,45 and other reports 47,48 …”
Section: How We Treat Advanced Sm In the Kit Inhibitor Era (Figure 4)supporting
confidence: 72%
See 2 more Smart Citations
“…Indeed, despite relatively short follow‐up in the EXPLORER and PATHFINDER studies, a non‐insignificant number of patients discontinued treatment due to disease progression 35,36 . Similar findings have been seen in the midostaurin studies 44,45 and other reports 47,48 …”
Section: How We Treat Advanced Sm In the Kit Inhibitor Era (Figure 4)supporting
confidence: 72%
“…In an SM‐AMN patient, discordant response of the two disease components to midostaurin therapy has been observed; that is AMN disease progression with concurrent SM response/remission, was observed in a setting where the AMN did not share the SM‐associated KIT D816V mutation 47 . In another report of three SM‐AMN patients, avapritinib treatment led to CR of the SM disease component, and all three patients were successfully bridged to SCT 48 .…”
Section: Analysis Of Clinical Trials With Kit‐targeted Tyrosine Kinas...mentioning
confidence: 97%
See 1 more Smart Citation